Clinical Trial Update: Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of sintilimab with surufatinib and temozolomide for advanced neuroendocrine carcinomas is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma

Drugs mentioned

• Sintilimab (sintilimab)
• Surufatinib (Surufatinib)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Neuroendocrine Carcinomas (NEC) | Phase 2 | Status: NOT_YET_RECRUITING